Tesamorelin
Tesamorelin is a synthetic analog of the full 44-amino-acid growth hormone-releasing hormone (GHRH) sequence with an added trans-3-hexenoic acid modification. It is the only GHRH analog currently FDA-approved, specifically indicated for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
Modified GHRH Analog - Visceral Fat Targeting
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine residue at position 1. This modification increases the peptide's stability and potency compared to native GHRH. It is marketed under the brand name Egrifta SV and was FDA-approved in 2010 for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Tesamorelin is the most potent GHRH analog available for clinical use, stimulating significantly greater growth hormone release than sermorelin or other GH secretagogues. Clinical trials demonstrated that tesamorelin reduced visceral adipose tissue (VAT) by an average of 15-18% without significant effects on subcutaneous fat, limb fat, or metabolic parameters. Emerging research has also explored tesamorelin's effects on cognitive function, with studies suggesting potential benefits for mild cognitive impairment and Alzheimer's risk biomarkers.
Aspire offers tesamorelin therapy through licensed U.S. 503A compounding pharmacies. All protocols are prescribed and monitored by Aspire clinicians with appropriate baseline and follow-up lab work, including IGF-1 levels, metabolic panels, and body composition assessment.
Proposed Mechanism of Action
Tesamorelin's enhanced potency comes from the trans-3-hexenoic acid modification at the N-terminus, which protects the peptide from enzymatic degradation and increases receptor binding affinity. This results in a more robust and sustained growth hormone pulse compared to sermorelin (which represents only the first 29 of 44 amino acids) or native GHRH. The amplified GH release drives downstream effects on IGF-1 production and tissue-specific metabolic responses.
The specificity of tesamorelin for visceral fat is one of its distinguishing characteristics. Visceral adipose tissue (VAT) is metabolically distinct from subcutaneous fat, with higher density of growth hormone receptors and greater responsiveness to GH-mediated lipolysis. This explains why tesamorelin reduces deep abdominal fat while having minimal effect on subcutaneous fat stores. Visceral fat is the more metabolically dangerous fat depot, associated with insulin resistance, cardiovascular risk, and systemic inflammation, making its selective reduction particularly clinically meaningful.
What Tesamorelin Is Being Explored For
These are the primary areas where Tesamorelin has been studied or discussed in the context of peptide therapy. Research depth varies by area.
How Tesamorelin Is Offered
Tesamorelin is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.
How Treatment Works
Peptide therapy at Aspire follows a clinician-guided process. Tesamorelin is not available for self-prescribing or anonymous purchase.
Tesamorelin FAQ
Tesamorelin has the strongest regulatory evidence of any GHRH analog, with FDA approval based on Phase 3 clinical trials involving over 800 patients. Post-approval research has expanded to cognitive function, metabolic syndrome, and non-alcoholic fatty liver disease. Its evidence base is robust and continues to grow, with active NIH-funded research in multiple therapeutic areas.
Ready to explore Tesamorelin?
Talk with an Aspire clinician about your goals and whether Tesamorelin therapy may be appropriate for you.
Text Us Now
